Fri, Sep 19, 2014, 11:19 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zillow, Inc. Message Board

eai_specialist 20 posts  |  Last Activity: Sep 15, 2014 9:04 AM Member since: Sep 20, 2001
  • eai_specialist eai_specialist Sep 15, 2014 9:04 AM Flag

    Thanks for AVNT C'dia... you might also want to check out RMTI. Seeking Alpha puts $58 price target and summer street reiterates $25 on Sept 10th and 11th...this is the next rocket in the bio space. RMTI saves lives!

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 12 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    Valuation and Price Target

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 11 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    Valuation and price target
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 11 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    Valuation and price target
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical Technologies (RMTI) Buy Rating Reiterated at Summer Street
    September 12, 2014 9:29 AM EDT
    Summer Street reiterated a Buy rating on Rockwell Medical Technologies (NASDAQ: RMTI) with a price target of $25. Analyst Jim ...

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 11 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    Valuation and price target
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 11 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    Valuation and price target
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 6 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 6 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.

    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval
    Sep. 10, 2014 4:05 PM ET | 6 comments | About: Rockwell Medical, Inc. (RMTI)
    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved.
    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

  • eai_specialist by eai_specialist Sep 11, 2014 8:57 AM Flag

    My base case scenario price target is $29 and is based on a 2016 P/E of 15. I believe that this is a very conservative valuation target for 2016 given the growth expectations for the next five years. I do not expect that the company will reach peak sales before 2020, and a 15 P/E for 2016 is quite a conservative target. The upside in the base case scenario is almost 200%.

    The bull case scenario assumes a 2016 P/E of 30, which I believe is realistic given the earnings growth estimates for the next couple of years. This translates into a $58 price target, which represents almost 500% upside from the current price. I know that these numbers seem unrealistic and mind-boggling, but this is what happens to stocks that have a new product on the market and an expected triple digit increase in revenues and earnings in the next couple of years.

    Sentiment: Strong Buy

  • eai_specialist by eai_specialist Sep 10, 2014 5:18 PM Flag

    Here's the article:

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval

    Sep. 10, 2014 4:05 PM ET | About: Rockwell Medical, Inc. (RMTI)

    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved

  • eai_specialist by eai_specialist Sep 10, 2014 5:12 PM Flag

    Here's the article:

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval

    Sep. 10, 2014 4:05 PM ET | About: Rockwell Medical, Inc. (RMTI)

    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved

  • eai_specialist by eai_specialist Sep 10, 2014 5:10 PM Flag

    Here's the Article:

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval -ABOUT F.T.
    .

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval

    Sep. 10, 2014 4:05 PM ET | About: Rockwell Medical, Inc. (RMTI)

    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved

  • eai_specialist by eai_specialist Sep 10, 2014 5:04 PM Flag

    Here's the Article:

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval -ABOUT F.T.
    .

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval

    Sep. 10, 2014 4:05 PM ET | About: Rockwell Medical, Inc. (RMTI)

    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved

  • eai_specialist by eai_specialist Sep 10, 2014 5:03 PM Flag

    Here's the Article:

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval -ABOUT F.T.
    .

    Rockwell Medical: Triple-Digit Upside Potential On Triferic Approval

    Sep. 10, 2014 4:05 PM ET | About: Rockwell Medical, Inc. (RMTI)

    Disclosure: The author is long RMTI. (More...)

    Summary
    •Rockwell Medical stands to benefit from Calcitriol, which was approved this year and the company is ready to launch in late 2014.
    •Triferic's approval in January 2015 would lead to significant upside.
    •Reward/risk ratio is highly skewed to the long side.
    •Additional downside should be limited even if Triferic does not get approved

  • Patient, Provider, Insurer, And Government Interests Aligned For 100% Upside On Rockwell Medical

    Sentiment: Strong Buy

  • Reply to

    RMTI is on the radar....

    by back10door Aug 13, 2014 10:58 PM
    eai_specialist eai_specialist Aug 14, 2014 5:47 AM Flag

    The FBR analyst, Andrew Berens is on his 7th or 8th job now. Holds them for 1-2 years. The guy use to be a doctor. Isn't that what Brean was? or did he just impersonate them? He was suspended by the SEC for impersonating doctors. Where do these guys come from? Any dips is a gift, but like Brean, this will pass over and will head to 13 soon. The IBB was heating up and guess the shorts needed another hit piece,

    Sentiment: Strong Buy

Z
130.97-1.05(-0.80%)Sep 19 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT